<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36146661</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1854</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14091854</ELocationID><Abstract><AbstractText>The research and development (R&amp;D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. Toward this end, we designed a novel single-stranded RNA-based adjuvant, L2, from the SARS-CoV-2 prototype genome. L2 could initiate retinoic acid-inducible gene-I signaling pathways to effectively activate the innate immunity. ZF2001, an aluminum hydroxide (Al) adjuvanted SARS-CoV-2 recombinant receptor binding domain (RBD) subunit vaccine with emergency use authorization in China, was used for comparison. L2, with adjuvant compatibility with RBD, elevated the antibody response to a level more than that achieved with Al, CpG 7909, or poly(I:C) as adjuvants in mice. L2 plus Al with composite adjuvant compatibility with RBD markedly improved the immunogenicity of ZF2001; in particular, neutralizing antibody titers increased by about 44-fold for Omicron, and the combination also induced higher levels of antibodies than CpG 7909/poly(I:C) plus Al in mice. Moreover, L2 and L2 plus Al effectively improved the Th1 immune response, rather than the Th2 immune response. Taken together, L2, used as an adjuvant, enhanced the immune response of the SARS-CoV-2 recombinant RBD protein vaccine in mice. These findings should provide a basis for the R&amp;D of novel RNA-based adjuvants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd., Changchun 130062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd., Beijing 102629, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kelei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd., Beijing 102629, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd., Changchun 130062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>5688UTC01R</RegistryNumber><NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance></Chemical><Chemical><RegistryNumber>5QB0T2IUN0</RegistryNumber><NameOfSubstance UI="D000536">Aluminum Hydroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000536" MajorTopicYN="N">Aluminum Hydroxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 recombinant protein vaccine</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">single-stranded RNA-based adjuvant</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36146661</ArticleId><ArticleId IdType="pmc">PMC9504790</ArticleId><ArticleId IdType="doi">10.3390/v14091854</ArticleId><ArticleId IdType="pii">v14091854</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 25 June 2022)].  Available online:  https://www.who.int/redirect-pages/page/novel-coronavirus-(covid-19)-situation-dashboard.</Citation></Reference><Reference><Citation>National Health Commission of the Peoples’ Republic of China  Novel Coronavirus Vaccination Status in Chinese Mainland.  [(accessed on 26 June 2022)]; Available online:  http://www.nhc.gov.cn/xcs/yqfkdt/202206/84b28c26fc5b4859a14034fc8fd85c4b.shtml.</Citation></Reference><Reference><Citation>Tracking SARS-CoV-2 Variants.  [(accessed on 25 June 2022)].  Available online:  https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</Citation></Reference><Reference><Citation>An Y., Li S., Jin X., Han J.B., Xu K., Xu S., Han Y., Liu C., Zheng T., Liu M., et al. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerg. Microbes Infect. 2022;11:1058–1071. doi: 10.1080/22221751.2022.2056524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2056524</ArticleId><ArticleId IdType="pmc">PMC9009945</ArticleId><ArticleId IdType="pubmed">35311493</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L., Zheng T., Xu K., Han Y., Xu L., Huang E., An Y., Cheng Y., Li S., Liu M., et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020;182:722–733.e711. doi: 10.1016/j.cell.2020.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.035</ArticleId><ArticleId IdType="pmc">PMC7321023</ArticleId><ArticleId IdType="pubmed">32645327</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K., Gao P., Liu S., Lu S., Lei W., Zheng T., Liu X., Xie Y., Zhao Z., Guo S., et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022;13:2265–2278. doi: 10.1016/j.cell.2022.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.029</ArticleId><ArticleId IdType="pmc">PMC9042943</ArticleId><ArticleId IdType="pubmed">35568034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B., P S.A., O’Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 2021;20:454–475. doi: 10.1038/s41573-021-00163-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00163-y</ArticleId><ArticleId IdType="pmc">PMC8023785</ArticleId><ArticleId IdType="pubmed">33824489</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascola J.R., Fauci A.S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 2020;20:87–88. doi: 10.1038/s41577-019-0243-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0243-3</ArticleId><ArticleId IdType="pmc">PMC7222935</ArticleId><ArticleId IdType="pubmed">31712767</ArticleId></ArticleIdList></Reference><Reference><Citation>Alving C.R., Peachman K.K., Matyas G.R., Rao M., Beck Z. Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev. Vaccines. 2020;19:279–292. doi: 10.1080/14760584.2020.1745636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1745636</ArticleId><ArticleId IdType="pmc">PMC7412170</ArticleId><ArticleId IdType="pubmed">32228108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni R.R., Rasheed M.A., Bhaumik S.K., Ranjan P., Cao W., Davis C., Marisetti K., Thomas S., Gangappa S., Sambhara S., et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J. Virol. 2014;88:13990–14001. doi: 10.1128/JVI.02273-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02273-14</ArticleId><ArticleId IdType="pmc">PMC4249139</ArticleId><ArticleId IdType="pubmed">25253340</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Singh V.K., Mishra A., Soudani E., Bakhru P., Singh C.R., Zhang D., Canaday D.H., Sheri A., Padmanabhan S., et al. NOD2/RIG-I Activating Inarigivir Adjuvant Enhances the Efficacy of BCG Vaccine Against Tuberculosis in Mice. Front. Immunol. 2020;11:592333. doi: 10.3389/fimmu.2020.592333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.592333</ArticleId><ArticleId IdType="pmc">PMC7751440</ArticleId><ArticleId IdType="pubmed">33365029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C., Beljanski V., Yin K., Olagnier D., Ben Y.F., Steel C., Goulet M.L., DeFilippis V.R., Streblow D.N., Haddad E.K., et al. Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists. J. Virol. 2015;89:8011–8025. doi: 10.1128/JVI.00845-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00845-15</ArticleId><ArticleId IdType="pmc">PMC4505665</ArticleId><ArticleId IdType="pubmed">26018150</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Zhang S., Yang Z., Lin H., Zhu J., Liu L., Wang W., Liu S., Liu W., Ma Y., et al. Self-Recognition of an Inducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response. Cell. 2018;173:906–919.e913. doi: 10.1016/j.cell.2018.03.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.064</ArticleId><ArticleId IdType="pubmed">29706547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin. Infect. Dis. 2008;46:1310–1314. doi: 10.1086/533467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/533467</ArticleId><ArticleId IdType="pubmed">18444872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.H., Bang Y.J., Park H.J., Li Ko H., Park S.I., Hwang K.A., Kim H., Nam J.H. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection. Vaccine. 2020;38:6141–6152. doi: 10.1016/j.vaccine.2020.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.07.022</ArticleId><ArticleId IdType="pubmed">32739118</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H.J., Bang E.K., Hong J.J., Lee S.M., Ko H.L., Kwak H.W., Park H., Kang K.W., Kim R.H., Ryu S.R., et al. Nanoformulated Single-Stranded RNA-Based Adjuvant with a Coordinative Amphiphile as an Effective Stabilizer: Inducing Humoral Immune Response by Activation of Antigen-Presenting Cells. Angew. Chem. Int. Ed. Engl. 2020;59:11540–11549. doi: 10.1002/anie.202002979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202002979</ArticleId><ArticleId IdType="pubmed">32239636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang Y.J., Hong S.H., Park H.J., Kwak H.W., Lee Y.S., Kim J.Y., Park H.J., Bae S.H., Kim H.J., Kim Y.H., et al. Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant. Sci Rep. 2021;11:11981. doi: 10.1038/s41598-021-91445-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91445-3</ArticleId><ArticleId IdType="pmc">PMC8184738</ArticleId><ArticleId IdType="pubmed">34099809</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne L.G., Reuschl A.K., Zuliani-Alvarez L., Whelan M.V.X., Turner J., Noursadeghi M., Jolly C., Towers G.J. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J. 2021;40:e107826. doi: 10.15252/embj.2021107826.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021107826</ArticleId><ArticleId IdType="pmc">PMC8209947</ArticleId><ArticleId IdType="pubmed">34101213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouwaki T., Nishimura T., Wang G., Oshiumi H. RIG-I-Like Receptor-Mediated Recognition of Viral Genomic RNA of Severe Acute Respiratory Syndrome Coronavirus-2 and Viral Escape From the Host Innate Immune Responses. Front. Immunol. 2021;12:700926. doi: 10.3389/fimmu.2021.700926.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700926</ArticleId><ArticleId IdType="pmc">PMC8267574</ArticleId><ArticleId IdType="pubmed">34249006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao T., Israelow B., Lucas C., Vogels C.B.F., Gomez-Calvo M.L., Fedorova O., Breban M.I., Menasche B.L., Dong H., Linehan M., et al. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. J. Exp. Med. 2022;219:e20211818. doi: 10.1084/jem.20211818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211818</ArticleId><ArticleId IdType="pmc">PMC8590200</ArticleId><ArticleId IdType="pubmed">34757384</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolico J.S., Lunardelli V.A.S., Yamamoto M.M., Cunha-Neto E., Boscardin S.B., Rosa D.S. Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine. Front. Immunol. 2019;10:843. doi: 10.3389/fimmu.2019.00843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00843</ArticleId><ArticleId IdType="pmc">PMC6492566</ArticleId><ArticleId IdType="pubmed">31105693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S., Chen H., Ma J., Chen Q., Deng H., Gong F., Huang H., Shi C. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection. J. Appl. Microbiol. 2013;115:1203–1211. doi: 10.1111/jam.12315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.12315</ArticleId><ArticleId IdType="pubmed">23902541</ArticleId></ArticleIdList></Reference><Reference><Citation>Autumn Smiley M., Sanford D.C., Triplett C.A., Callahan D., Frolov V., Look J., Ruiz C., Reece J.J., Miles A., Ruiz E., et al. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909. Vaccine. 2019;37:6356–6361. doi: 10.1016/j.vaccine.2019.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.015</ArticleId><ArticleId IdType="pmc">PMC6764848</ArticleId><ArticleId IdType="pubmed">31530467</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Mao Q., An C., Zhang J., Gao F., Bian L., Li C., Liang Z., Xu M., Wang J. Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg. Microbes Infect. 2021;10:629–637. doi: 10.1080/22221751.2021.1902245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1902245</ArticleId><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Song Z., Yang J., He Q., Mao Q., Bai Y., Liu J., An C., Yan X., Cui B., et al. Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV. Emerg. Microbes Infect. 2022;11:1145–1153. doi: 10.1080/22221751.2022.2059404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2059404</ArticleId><ArticleId IdType="pmc">PMC9037177</ArticleId><ArticleId IdType="pubmed">35343384</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Mao Q., Peng X., He Z., Lu S., Zhang J., Gao F., Bian L., An C., Yu W., et al. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. Signal. Transduct. Target. Ther. 2022;7:69. doi: 10.1038/s41392-022-00926-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00926-y</ArticleId><ArticleId IdType="pmc">PMC8892123</ArticleId><ArticleId IdType="pubmed">35241645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., He Q., An C., Mao Q., Gao F., Bian L., Wu X., Wang Q., Liu P., Song L., et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg. Microbes Infect. 2021;10:1598–1608. doi: 10.1080/22221751.2021.1957401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1957401</ArticleId><ArticleId IdType="pmc">PMC8381941</ArticleId><ArticleId IdType="pubmed">34278956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Gao F., Zhang J., He Q., Mao Q., Xu M., Liang Z. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev. Vaccines. 2021;20:365–373. doi: 10.1080/14760584.2021.1903879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1903879</ArticleId><ArticleId IdType="pmc">PMC8054487</ArticleId><ArticleId IdType="pubmed">33851875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., Wang Q., Liu M., Bian L., Liu J., Gao F., Mao Q., Wang Z., Wu X., Xu M., et al. The next major emergent infectious disease: Reflections on vaccine emergency development strategies. Expert Rev. Vaccines. 2022;21:471–481. doi: 10.1080/14760584.2022.2027240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2027240</ArticleId><ArticleId IdType="pubmed">35080441</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Zhou J., Xu W., Deng W., Wang Y., Wang M., Wang Q., Hsieh M., Dong J., Wang X., et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022;32:269–287. doi: 10.1038/s41422-022-00612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00612-2</ArticleId><ArticleId IdType="pmc">PMC8767042</ArticleId><ArticleId IdType="pubmed">35046518</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi M., Sadahira T., Ueki H., Kinoshita R., Murata H., Yamamoto K.I., Futami J., Nasu Y., Ochiai K., Kumon H., et al. Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements. Oncol. Rep. 2017;38:1108–1114. doi: 10.3892/or.2017.5710.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2017.5710</ArticleId><ArticleId IdType="pubmed">28627633</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N.N., Li X.F., Deng Y.Q., Zhao H., Huang Y.J., Yang G., Huang W.J., Gao P., Zhou C., Zhang R.R., et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182:1271–1283.e1216. doi: 10.1016/j.cell.2020.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7377714</ArticleId><ArticleId IdType="pubmed">32795413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W., Zhang X., Drelich A., Shi J., Hsu J.C., Luchsinger L., Hillyer C.D., Tseng C.K., Jiang S., Du L. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020;30:932–935. doi: 10.1038/s41422-020-0387-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0387-5</ArticleId><ArticleId IdType="pmc">PMC7403570</ArticleId><ArticleId IdType="pubmed">32759966</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Jr., Lisa A., Purcell L.A., Kawaoka Y., Corti D., Fremont D.H., et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. 2021 doi: 10.1101/2021.12.15.472828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.15.472828</ArticleId><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Li Y., Dai L., Wang J., He P., Li C., Fang X., Wang C., Zhao X., Huang E., et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 2021;21:1107–1119. doi: 10.1016/S1473-3099(21)00127-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00127-4</ArticleId><ArticleId IdType="pmc">PMC7990482</ArticleId><ArticleId IdType="pubmed">33773111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Bai Y., Gao F., Liu M., He Q., Wu X., Mao Q., Xu M., Liang Z. Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice. Virol. J. 2022;19:1–5. doi: 10.1186/s12985-022-01818-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01818-x</ArticleId><ArticleId IdType="pmc">PMC9122244</ArticleId><ArticleId IdType="pubmed">35596222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbaghi A., Malek M., Abdolahi S., Miri S.M., Alizadeh L., Samadi M., Mohebbi S.R., Ghaemi A. A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma-irradiated influenza vaccine. Virol. J. 2021;18:201. doi: 10.1186/s12985-021-01672-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01672-3</ArticleId><ArticleId IdType="pmc">PMC8501930</ArticleId><ArticleId IdType="pubmed">34627297</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanishi E., Borriello F., O’Meara T.R., McGrath M.E., Saito Y., Haupt R.E., Seo H.S., van Haren S.D., Cavazzoni C.B., Brook B., et al. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Sci. Transl. Med. 2021;14:eabj5305. doi: 10.1126/scitranslmed.abj5305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj5305</ArticleId><ArticleId IdType="pmc">PMC10176044</ArticleId><ArticleId IdType="pubmed">34783582</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Li D., Ruan W., Chen Z., Zhang R., Zheng A., Qiao S., Zheng X., Zhao Y., Dai L., et al. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. N. Engl. J. Med. 2022;386:894–896. doi: 10.1056/NEJMc2119426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119426</ArticleId><ArticleId IdType="pmc">PMC8809506</ArticleId><ArticleId IdType="pubmed">35081296</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Zhou B., Cheng L., Liu W., Fan Q., Ge X., Peng H., Fu Y.X., Ju B., Zhang Z. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Virol J. 2022;19:2. doi: 10.1186/s12985-021-01737-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01737-3</ArticleId><ArticleId IdType="pmc">PMC8724645</ArticleId><ArticleId IdType="pubmed">34983583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Stralin K., Gorin J.B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158–168.e114. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstad-Bakke B., Lee W., Chandrasekar S.S., Gasper D.J., Salas-Quinchucua C., Cleven T., Sullivan J.A., Talaat A., Osorio J.E., Suresh M. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. USA. 2022;119:e2118312119. doi: 10.1073/pnas.2118312119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118312119</ArticleId><ArticleId IdType="pmc">PMC9171754</ArticleId><ArticleId IdType="pubmed">35561224</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C., Albert G., Cho I., Robertson A., Reed P., Neal S., Plested J.S., Zhu M., Cloney-Clark S., Zhou H., et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 2020;383:2320–2332. doi: 10.1056/NEJMoa2026920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026920</ArticleId><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>